2024. Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s422. DOI:https://doi.org/10.25251/skin.8.supp.422.